Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Janssen Introduces Business Units for Sales & Marketing
January 11, 2010
- Fulvestrant Applied for Postmenopausal Breast Cancer
January 11, 2010
- 5,032 Applicants for 16th Examination for MR Certification
January 11, 2010
- AFM to Manage Supply of All Drugs to Hospitals
January 11, 2010
- Tamiflu Approved for Prevention in Infants, Children
January 11, 2010
- Korosho to Reallocate Increased Medical Fees
January 11, 2010
- Kowa to Copromote Livalo with Lilly in the US
January 11, 2010
- Bup-4 Approved for Problems Associated with OAB
January 11, 2010
- Only 10% of Consumers Fail to Buy Class 1 OTC Drugs due to Absence of Pharmacists
January 11, 2010
- Ranbaxy to Market Olmesartan in 6 African Countries
January 11, 2010
- Pricing System Reform to Trigger Industry Reorganization
January 11, 2010
- Aricept's Medicoeconomic Benefits Demonstrated
January 11, 2010
- Bayer to Integrate Intendis in April
January 11, 2010
- Pfizer to Break Away from Dependence on Blockbusters: New President Umeda
January 11, 2010
- Female Doctors Tend to Stay Away from Surgery Dept.: Korosho
January 11, 2010
- Welfide Korea Renamed Mitsubishi Tanabe Pharma Korea
January 11, 2010
- FDA Advisory Committee Votes in Favor of Line Extension for Crestor
January 11, 2010
- Toho to Completely Acquire Asucome in February
January 11, 2010
- Coefficient for Generics Not to Be Introduced This April
January 11, 2010
- FPMAJ, JPMA Welcome New Premium as a Step toward New Pricing System
January 11, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…